SuperworthOramed Pharmaceuticals EPS ORMP
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $4.11
- Latest quarter, Q2 FY26
- $1.84
- +494% on a year earlier
- Fiscal year 2025
- $1.48
Oramed Pharmaceuticals' earnings per share was $4.11 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $1.84, up 494% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $1.48 | n/a |
| FY2024 | −$0.47 | −462% |
| FY2023 | $0.13 | n/a |
| FY2022 | −$0.94 | n/a |
| FY2021 | n/a | n/a |
| FY2020 | −$0.39 | n/a |
| FY2019 | −$0.82 | −264% |
| FY2018 | $0.50 | +28% |
| FY2017 | $0.39 | n/a |
| FY2016 | −$0.81 | −361% |
| FY2015 | $0.31 | +11% |
| FY2014 | $0.28 | +600% |
| FY2013 | $0.04 | −75% |
| FY2012 | $0.16 | n/a |
| FY2011 | $0.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $1.84 | +494% | $4.11 | |
| Q1 FY26 | $0.91 | n/a | $2.58 | |
| Q4 FY25 | $0.23 | n/a | $1.48 | |
| Q3 FY25 | $1.13 | n/a | $1.00 | |
| Q2 FY25 | $0.31 | +41% | −$0.61 | |
| Q1 FY25 | −$0.19 | −575% | −$0.70 | |
| Q4 FY24 | −$0.25 | −178% | −$0.47 | |
| Q3 FY24 | −$0.48 | n/a | $0.10 | |
| Q2 FY24 | $0.22 | n/a | $0.50 | |
| Q1 FY24 | $0.04 | n/a | $0.25 | |
| Q4 FY23 | $0.32 | n/a | $0.13 | |
| Q3 FY23 | −$0.08 | n/a | −$0.41 |
Against its peers
Companies in Drug Manufacturers - General nearest Oramed Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ORMPOramed Pharmaceuticals | $4.11 | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| LFVNLifevantage | $0.40 | −46% a year |
| SPROSpero Therapeutics | $0.11 | |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| Peer median | $0.65 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Oramed Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.